Cencora, Inc. (NYSE:COR) Stock Holdings Cut by Pensionfund Sabic

Pensionfund Sabic lessened its position in Cencora, Inc. (NYSE:COR) by 10.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,200 shares of the company’s stock after selling 600 shares during the period. Pensionfund Sabic’s holdings in Cencora were worth $1,170,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of COR. Strategic Wealth Partners Ltd. boosted its holdings in Cencora by 2.7% during the third quarter. Strategic Wealth Partners Ltd. now owns 23,657 shares of the company’s stock worth $5,325,000 after buying an additional 624 shares in the last quarter. Gratus Wealth Advisors LLC lifted its position in shares of Cencora by 2.4% during the 3rd quarter. Gratus Wealth Advisors LLC now owns 8,974 shares of the company’s stock valued at $1,970,000 after acquiring an additional 214 shares during the last quarter. Insight Wealth Strategies LLC boosted its stake in shares of Cencora by 2.3% during the 3rd quarter. Insight Wealth Strategies LLC now owns 9,017 shares of the company’s stock worth $2,030,000 after acquiring an additional 202 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its stake in shares of Cencora by 15.2% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock worth $262,000 after acquiring an additional 154 shares in the last quarter. Finally, Callan Family Office LLC grew its holdings in shares of Cencora by 33.7% in the 3rd quarter. Callan Family Office LLC now owns 1,718 shares of the company’s stock worth $387,000 after acquiring an additional 433 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $222.20 on Friday. The firm has a market cap of $44.32 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.58 and a beta of 0.44. Cencora, Inc. has a 1 year low of $182.75 and a 1 year high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The business has a fifty day simple moving average of $233.47 and a 200 day simple moving average of $231.62.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. During the same period in the previous year, the company earned $2.92 EPS. The firm’s revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.92%. Cencora’s dividend payout ratio is currently 22.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday. Evercore ISI dropped their target price on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday. Bank of America restated a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.